Phase II Psi-Gad data should light a fuse under this platform - Q1 2024the March interim were solid - no trial mitigations or 'redesigns' required same same dosing, safety and efficacy - zero adverse events in the trial cohort ....that alone is significant
we know the fast tracking was getting the clinic set up and progressing Authorised Prescriber HREC endorsement ....yep - ducks lining up
this is looking really good at this point - there will be deep interest from US investors on the back of the trial data
General discussion, page-18939
-
- There are more pages in this discussion • 1,285 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)